Latest Insider Transactions at Oramed Pharmaceuticals Inc. (ORMP)
This section provides a real-time view of insider transactions for Oramed Pharmaceuticals Inc. (ORMP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ORAMED PHARMACEUTICALS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ORAMED PHARMACEUTICALS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2022
|
Kevin Rakin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,010
-5.04%
|
$30,100
$10.63 P/Share
|
|
Feb 17
2022
|
Kevin Rakin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+10.05%
|
$26,668
$4.8 P/Share
|
|
Feb 11
2022
|
Kevin Rakin Director |
SELL
Bona fide gift
|
Direct |
5,000
-9.61%
|
-
|
|
Jan 09
2022
|
Netanel Derovan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+50.0%
|
-
|
|
Jan 03
2022
|
Aviad Friedman Director |
SELL
Bona fide gift
|
Direct |
6,000
-100.0%
|
-
|
|
Jan 03
2022
|
Aviad Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jan 03
2022
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+21.59%
|
-
|
|
Jan 03
2022
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+14.45%
|
-
|
|
Jan 03
2022
|
Kevin Rakin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+9.37%
|
-
|
|
Jan 03
2022
|
Michael Rabinowitz Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+14.79%
|
-
|
|
Jan 03
2022
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+18.61%
|
-
|
|
Jan 03
2022
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
213,000
+10.01%
|
-
|
|
Jan 03
2022
|
Nadav Kidron President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
48,752
-5.21%
|
$633,776
$13.89 P/Share
|
|
Jan 03
2022
|
Arie Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+40.0%
|
-
|
|
Jan 03
2022
|
Leonard Sank Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Dec 30
2021
|
Nadav Kidron President and CEO |
SELL
Bona fide gift
|
Direct |
20,000
-2.54%
|
-
|
|
Dec 28
2021
|
Michael Rabinowitz Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,532
-9.53%
|
$114,384
$12.98 P/Share
|
|
Dec 28
2021
|
Nadav Kidron President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,728
-3.88%
|
$380,736
$12.98 P/Share
|
|
Dec 16
2021
|
Kevin Rakin Director |
SELL
Bona fide gift
|
Direct |
5,000
-8.77%
|
-
|
|
Dec 03
2021
|
Nadav Kidron President and CEO |
SELL
Bona fide gift
|
Direct |
20,000
-2.39%
|
-
|
|
Nov 01
2021
|
Arie Mayer Director |
SELL
Open market or private sale
|
Direct |
3,000
-100.0%
|
$75,000
$25.6 P/Share
|
|
Sep 16
2021
|
Kevin Rakin Director |
SELL
Open market or private sale
|
Direct |
21,100
-27.02%
|
$422,000
$20.99 P/Share
|
|
Sep 01
2021
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Aug 31
2021
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+11.78%
|
-
|
|
Aug 31
2021
|
Kevin Rakin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+11.35%
|
-
|
|
Aug 31
2021
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+24.39%
|
-
|
|
Aug 31
2021
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+32.0%
|
-
|
|
Aug 09
2021
|
Nadav Kidron President and CEO |
SELL
Open market or private sale
|
Direct |
220,000
-25.33%
|
$4,400,000
$20.11 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
26,093
-10.82%
|
$547,953
$21.09 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
79,136
+25.91%
|
$395,680
$5.74 P/Share
|
|
Aug 04
2021
|
Michael Rabinowitz Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Feb 26
2021
|
Leonard Sank Director |
SELL
Other acquisition or disposition
|
Indirect |
453,125
-100.0%
|
$1,359,375
$3.68 P/Share
|